A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation

Phase 3

Active, not recruiting

• Conditions: Chronic Lymphocytic Leukemia (CLL)
• Interventions: Drug: Obinutuzumab; Drug: Fludarabine; Drug: Venetoclax; Drug: Cyclophosphamide; Drug: Rituximab; Drug: Bendamustine

• Registration Number: NCT04285567
• Lead Sponsor: Hoffmann-La Roche

Brief Summary

This study will evaluate the efficacy and safety of venetoclax and obinutuzumab (VEN + G) compared with fludarabine + cyclophosphamide + rituximab or bendamustine + rituximab (FCR/BR) in FIT participants (FIT is defined by a cumulative illness rating scale \[CIRS\]/score of ≤6 and a normal creatinine clearance of ≥70 mL/min) with previously untreated CLL without DEL(17P) or TP53 mutation requiring treatment. Eligible participants will be randomly assigned in a 1:1 ratio to receive either VEN + G (Arm A) or FCR/BR (Arm B).

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-02-25
• Study First Submitted QC: 2020-02-25
• Study First Posted: 2020-02-26
• Study Start: 2020-05-28
• Primary Completion: 2024-03-19
• Results First Submitted: 2025-03-13
• Status Verified: 2025-04
• Results First Submitted QC: 2025-04-16
• Last Update Submitted: 2025-04-16
• Results First Posted: 2025-04-17
• Last Update Posted: 2025-04-17
• Study Completion: 2026-07-31

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 166

Inclusion Criteria

• Ability to comply with the study protocol, in the investigator's judgment

• Aged 18 years or older

• Have previously untreated documented Chronic Lymphocytic Leukemia (CLL) according to the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria

• CLL requiring treatment according to the iwCLL criteria

• Cumulative Illness Rating Scale (CIRS) score ≤ 6 and creatinine clearance (CrCl) ≥ 70 mL/min

• Hematology values within the following limits, unless cytopenia is caused by the underlying disease (i.e., no evidence of additional bone marrow (BM) dysfunction; e.g., myelodysplastic syndrome, hypoplastic BM):

  • Absolute neutrophil count ≥ 1.0 x 109/L, unless there is BM involvement
  • Platelet count ≥ 75 x 109/L and more than 7 days since last transfusion, or ≥ 30 x 109/L if there is BM involvement

• Adequate liver function as indicated by a total bilirubin, aspartate aminotransferase, and Alanine transaminase ≤ 2 times the institutional upper limit of normal (ULN) value, unless directly attributable to the participant's CLL

• Life expectancy >6 months

• For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception and agreement to refrain from donating eggs

• For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, and agreement to refrain from donating sperm

Exclusion Criteria

• Transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL)

• Participants with Small Lymphocyclic Lymphoma (SLL) only

• Known central nervous system involvement

• Participants with a history of confirmed progressive multifocal leukoencephalopathy (PML)

• Detected del(17p) or TP53 mutation (valid test within 6-months from screening is required for randomisation)

• An individual organ/system impairment score of 4 as assessed by the Cumulative Illness Rating Scale (CIRS) definition limiting the ability to receive the treatment regimen of this trial with the exception of eyes, ears, nose, throat organ system

• Participants with uncontrolled autoimmune hemolytic anemia or immune thrombocytopenia

• History of prior malignancy

• Participants with infections requiring IV treatment (Grade 3 or 4) within the last 8 weeks prior to enrollment

• Evidence of other clinically significant uncontrolled conditions including but not limited to active or uncontrolled systemic infection (e.g., viral, bacterial, or fungal)

• History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products

• Hypersensitivity to fludarabine, bendamustine, cyclophosphamide, rituximab, obinutuzumab, or venetoclax or to any of the excipients (e.g., trehalose)

• Pregnant women and nursing mothers

• Vaccination with a live vaccine ≤ 28 days prior to randomization

• Prisoners or participants who are institutionalized by regulatory or court order or persons who are in dependence to the Sponsor or an investigator

• History of illicit drug or alcohol abuse within 12 months prior to screening, in the investigator's judgment

• Positive test results for chronic hepatitis B virus (HBV) infection (defined as positive hepatitis B surface antigen [HBsAg] serology)

• Positive test result for hepatitis C (hepatitis C virus [HCV] antibody serology testing)

• Participants with known infection with HIV or Human T-Cell Leukemia Virus 1 (HTLV-1)

• Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the participant's safe participation in and completion of the study

• Received any of the following agents within 28 days prior to the first dose of study treatment:

  • Immunotherapy
  • Radiotherapy
  • Hormone therapy
  • Any therapies intended for the treatment of lymphoma/leukemia whether approved or experimental

• Participants who have received the following agents:

  • Strong and moderate CYP3A inhibitors/inducers within 7 days prior to the initiation of study treatment
  • Steroid therapy for anti-neoplastic intent with the exception of inhaled steroids for asthma, topical steroids, or replacement/stress corticosteroids within 7 days prior to the first dose of study drug administration
  • Consumed grapefruit, grapefruit products, Seville oranges(including marmalade containing Seville oranges), or star fruit within 3 days prior to the first dose of study drug and throughout venetoclax administration

• Inability to swallow a large number of tablets.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
VEN + G	Obinutuzumab	Participants will receive 12 cycles of treatment (each cycle is 28 days). Venetoclax (VEN) will be administered orally, daily, with a 5-week ramp-up period, starting on Cycle 1, Day 22 and administration will continue until the end of Cycle 12. Obinutuzumab (G) will be administered intravenously (IV) on Days 1 (and 2), 8, and 15 of Cycle 1 and on Day 1 of Cycles 2-6.
VEN + G	Venetoclax	Participants will receive 12 cycles of treatment (each cycle is 28 days). Venetoclax (VEN) will be administered orally, daily, with a 5-week ramp-up period, starting on Cycle 1, Day 22 and administration will continue until the end of Cycle 12. Obinutuzumab (G) will be administered intravenously (IV) on Days 1 (and 2), 8, and 15 of Cycle 1 and on Day 1 of Cycles 2-6.
FCR/BR	Cyclophosphamide	Participants will receive 6 cycles of Fludarabine + Cyclophosphamide + Rituximab (FCR) consisting of a single cycle of a single infusion of rituximab on Day 1 and fludarabine and cyclophosphamide infusions on Days 1-3 of each 28-day cycle or bendamustine (B) as infusions on Days 1 and 2 and a single cycle of rituximab on Day 1 of each 28-day cycle.
FCR/BR	Fludarabine	Participants will receive 6 cycles of Fludarabine + Cyclophosphamide + Rituximab (FCR) consisting of a single cycle of a single infusion of rituximab on Day 1 and fludarabine and cyclophosphamide infusions on Days 1-3 of each 28-day cycle or bendamustine (B) as infusions on Days 1 and 2 and a single cycle of rituximab on Day 1 of each 28-day cycle.
FCR/BR	Rituximab	Participants will receive 6 cycles of Fludarabine + Cyclophosphamide + Rituximab (FCR) consisting of a single cycle of a single infusion of rituximab on Day 1 and fludarabine and cyclophosphamide infusions on Days 1-3 of each 28-day cycle or bendamustine (B) as infusions on Days 1 and 2 and a single cycle of rituximab on Day 1 of each 28-day cycle.
FCR/BR	Bendamustine	Participants will receive 6 cycles of Fludarabine + Cyclophosphamide + Rituximab (FCR) consisting of a single cycle of a single infusion of rituximab on Day 1 and fludarabine and cyclophosphamide infusions on Days 1-3 of each 28-day cycle or bendamustine (B) as infusions on Days 1 and 2 and a single cycle of rituximab on Day 1 of each 28-day cycle.

Primary Outcome Measures

Name	Time	Method
Minimal Residual Disease (MRD) Response Rate Measured in Peripheral Blood (PB) Using Next Generation Sequencing (NGS)	At Month 15	MRD response rate was determined as the percentage of participants with MRD-negativity measured in the PB using NGS using a cutoff of \< 10\^-4. MRD was considered negative if the result was \< 1 CLL cell in 10,000 leukocytes. Percentages have been rounded off to the nearest decimal point.

Secondary Outcome Measures

Name	Time	Method
Change From Baseline in Physical Functioning, Role Functioning and Health-Related Quality of Life (HRQoL) Assessed Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQC-30)	VEN + G: Day 1 of Cycle 1-12, Day 28 after treatment completion/early termination (TC/ET), follow up (FU) visits; FCR/BR: Day 1 of Cycle 1-6, Day 28 after TC/ET, end of combination treatment response visit and FU visit (up to 74 months) (1 cycle=28 days)	The EORTC QLQ-C30 consists of 30 questions incorporated into five functional scales (physical, role, cognitive, emotional and social scales), three symptom scales (fatigue, pain, nausea, and vomiting scales), a global health status/global quality-of-life (GHS/QoL) scale, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The 28 function and symptom items were scored on a 4-point scale that ranged from "not at all" to "very much," and the 2 GHS/QoL items were scored on a 7-point scale that ranged from "very poor" to "excellent." Raw average scale scores were linearly transformed to range 0-100 with higher scores indicating higher response levels (i.e. higher functioning, higher symptom severity).
Change From Baseline in M.D. Anderson Symptom Inventory-CLL (MDASI-CLL) Score	VEN + G: Day 1 of Cycle 1-12, Day 28 after TC/ET, FU visits; FCR/BR: Day 1 of Cycle 1-6, Day 28 after TC/ET, end of combination treatment response visit and FU visit (up to approximately 74 months) (1 cycle=28 days)	MDASI-CLL consists of 25 items over 3 scales that assess core cancer \& CLL-related symptom severity, as well as symptom interference that a participant may have experienced in past 24 hours. Participants were asked to rate severity of 13 symptoms called mean core symptom severity (pain, fatigue, nausea, disturbed sleep, distressed, shortness of breath, remembering things, lack of appetite, drowsy, dry mouth, sadness, vomiting \& numbness/tingling), 6 disease-specific symptoms called mean module symptom severity (night sweats, fever \& chills, lymph node swelling, diarrhea, easy bruising/bleeding \& constipation) \& 6 mean interference on life questions (general activity, walking, work, mood, relations with other people \& enjoyment of life) on a scale from 0-10 with 0 indicating that symptom is "not present" or "did not interfere" with participant's activities \& 10 indicating "as bad as you can imagine" or "interfered completely". Lower scores indicated lower symptom severity/interference.
Progression-free Survival (PFS)	Up to approximately 74 months	PFS was defined as the time from randomization to the first occurrence of disease progression (PD), or death from any cause. PD was assessed by the investigators using the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria. PD was defined as any one of the following: Appearance of any new lesion such as enlarged lymph nodes (≥ 1.5 centimeters \[cm\]); increase by ≥ 50% in greatest diameter of any previous site (≥ 1.5 cm); increase in the spleen/liver size by ≥ 50% or de novo appearance of splenomegaly/hepatomegaly; increase in blood lymphocytes by 50% or more with at least 5x10\^9/litres (L) B lymphocytes; transformation to a more aggressive histology; occurrence of cytopenia; posttreatment: progression of any cytopenia, documented by a decrease of hemoglobin (Hb) ≥ 2 grams per deciliter (g/dL) or 10 g/dL, or by a decrease of platelet counts ≥ 50%/100x10\^9/L, which occurs at least 3 months after treatment.
MRD Response Rate in PB of FCR/BR Compared With VEN+G at the End of Treatment Response Visit	VEN+G: From Cycle 1 Day 1 up to 15 months; FCR/BR: From Cycle 1 Day 1 up to 9 months (1 cycle=28 days)	MRD response rate was determined as the percentage of participants with MRD-negativity measured in the PB using NGS using a cutoff of \< 10\^-4. MRD was considered negative if the result was \< 1 CLL cell in 10,000 leukocytes. Percentages have been rounded off to the nearest decimal point.
MRD Response Rate in Bone Marrow (BM) of FCR/BR Compared With VEN+G at the End of Treatment Response Visit	VEN+G: From Cycle 1 Day 1 up to 15 months; FCR/BR: From Cycle 1 Day 1 up to 9 months (1 cycle=28 days)	MRD response rate=percentage of participants with MRD-negativity measured in BM using NGS (cutoff of \<10\^-4). MRD negativity=\<1 CLL cell in 10,000 leukocytes. MRD in BM was assessed for participants with complete response (CR)/CR with incomplete blood count recovery (CRi) \& partial response (PR). CR=PB lymphocytes \<4x10\^9 /L; Absence of significant lymphadenopathy (nodes \<1.5 cm in longest diameter); no hepatomegaly/splenomegaly; absence of disease/constitutional symptoms; BM at least normocellular for age, ≤30% of nucleated cells being lymphocytes. CRi=fulfilling CR criteria but with persistent anemia/thrombocytopenia/neutropenia. PR= ≥50% decrease in PB lymphocyte count from pre-treatment value; ≥50% reduction in lymphadenopathy (sum of longest diameter of up to 6 largest lymph nodes by physical exam \& 50% reduction in the sum of product of the diameter of up to 6 largest lymph nodes); ≥50% reduction of liver/spleen enlargement/normalization in size, if enlarged at baseline.
Objective Response Rate (ORR)	At Month 15	ORR was defined as the percentage of participants with overall response (OR) of CR, CRi, and PR as determined by the investigator according to the iwCLL guidelines. CR was defined as PB lymphocytes \<4x10\^9 /L; absence of significant lymphadenopathy (nodes \<1.5 cm in longest diameter \[LD\]); no hepatomegaly/splenomegaly; absence of disease/constitutional symptoms; BM at least normocellular for age, ≤30% of nucleated cells being lymphocytes. CRi was defined as fulfilling CR criteria but with persistent anemia/thrombocytopenia/neutropenia. PR was defined as ≥50% decrease in PB lymphocyte count from pre-treatment value; ≥50% reduction in lymphadenopathy sum of longest diameter of up to 6 largest lymph nodes by physical exam and 50% reduction in the sum of product of the diameter of up to 6 largest lymph nodes); ≥50% reduction of liver/spleen enlargement/normalization in size, if enlarged at baseline.
CR Rate	At Month 15	CR rate was defined as the percentage of participants with CR or CRi. CR/CRi were defined according to the iwCLL guidelines. CR was defined as one of the following: PB lymphocytes (evaluated by blood and differential count) below 4 x 10\^9 /L; absence of significant lymphadenopathy (nodes \< 1.5 cm in LD or any extra nodal disease); no hepatomegaly; no splenomegaly; absence of disease or constitutional symptoms; BM at least normocellular for age, ≤30% of nucleated cells being lymphocytes. CRi was defined as participants fulfilling CR criteria but had persistent anemia, thrombocytopenia, or neutropenia. Percentages have been rounded off to the nearest decimal point.
MRD Response Rate in PB of Participants With a CR/CRi at the End of Treatment Visit	At Month 15	MRD response rate was determined as the percentage of participants (with a CR/CRi) with MRD-negativity measured in the PB using NGS using a cutoff of \< 10\^-4. MRD was considered negative if the result was \< 1 CLL cell in 10,000 leukocytes. CR/CRi were defined according to the iwCLL guidelines. CR was defined as one of the following: PB lymphocytes below 4 x 10\^9 /L; absence of significant lymphadenopathy (nodes \< 1.5 cm in LD or any extra nodal disease); no hepatomegaly; no splenomegaly; absence of disease or constitutional symptoms; BM at least normocellular for age, ≤30% of nucleated cells being lymphocytes. CRi was defined as participants fulfilling CR criteria but had persistent anemia, thrombocytopenia, or neutropenia. Percentages have been rounded off to the nearest decimal point.
MRD Response Rate in BM of Participants With a CR/CRi at the End of Treatment Visit	VEN+G: From Cycle 1 Day 1 up to 15 months; FCR/BR: From Cycle 1 Day 1 up to 9 months (1 cycle=28 days)	MRD response rate was determined as the percentage of participants (with CR/CRi) with MRD-negativity measured in the BM using NGS using a cutoff of \< 10\^-4. MRD was considered negative if the result was \< 1 CLL cell in 10,000 leukocytes. CR/CRi were defined according to the iwCLL guidelines. CR was defined as one of the following: PB lymphocytes below 4 x 10\^9 /L; absence of significant lymphadenopathy (nodes \< 1.5 cm in LD or any extra nodal disease); no hepatomegaly; no splenomegaly; absence of disease or constitutional symptoms; BM at least normocellular for age, ≤30% of nucleated cells being lymphocytes. CRi was defined as participants fulfilling CR criteria with CR but had persistent anemia, thrombocytopenia, or neutropenia. Percentages have been rounded off to the nearest decimal point.
Duration of Objective Response (DOR)	Up to approximately 74 months	DOR was defined as the time from the first occurrence of a documented OR (CR, CRi and PR) to the time of PD as determined by the investigator, or death from any cause, whichever occurs first. CR, CRi, PR, and PD were defined according to the iwCLL guidelines. PD was defined as any one of the following: appearance of any new lesion such as enlarged lymph nodes (≥ 1.5 cm); increase by ≥ 50% in greatest diameter of any previous site (≥ 1.5 cm); increase in the spleen/liver size by ≥ 50% or de novo appearance of splenomegaly/hepatomegaly; increase in blood lymphocytes by 50% or more with at least 5x10\^9/L B lymphocytes; transformation to a more aggressive histology; occurrence of cytopenia; posttreatment: progression of any cytopenia, documented by a decrease of Hb ≥ 2 g/dL or 10 g/dL, or by a decrease of platelet counts ≥ 50%/100x10\^9/L, which occurs at least 3 months after treatment. CR, CRi and PR were defined as outlined in the description for ORR outcome measure (OM) number 5.
Best Overall Response (BOR)	At Month 15	BOR=percentage of participants with CR/CRi/PR/stable disease (SD)/PD per the investigator. Participants with best response as CR/CRi/PR were considered responders while those reaching SD/PD were non-responders. SD=participants who have not achieved a CR or a PR, or who have not exhibited PD. PD=any one of the following: appearance of any new lesion such as enlarged lymph nodes (≥ 1.5 cm); increase by ≥ 50% in greatest diameter of any previous site (≥ 1.5 cm); increase in the spleen/liver size by ≥ 50% or de novo appearance of splenomegaly/hepatomegaly; increase in blood lymphocytes by 50% or more with at least 5x10\^9/L B lymphocytes; transformation to a more aggressive histology; occurrence of cytopenia; posttreatment: progression of any cytopenia, documented by a decrease of Hb ≥ 2 g/dL or 10 g/dL, or by a decrease of platelet counts ≥ 50%/100x10\^9/L, which occurs at least 3 months after treatment. CR, CRi and PR were defined as outlined in the description for ORR, OM number 5.
VEN + G: Tumor Lysis Syndrome (TLS) Risk Reduction Rate	Baseline up to Cycle 1 Day 22 (1 cycle=28 days)	TLS risk reduction rate in the VEN + G arm was defined as the reduction in the percentage of participants who were TLS high-risk after 3 doses of obinutuzumab compared to the percentage of participants who were TLS high-risk at baseline. Risk for developing TLS were categorised into: Low - All measurable lymph nodes with the LD \< 5 cm and \< 25x10\^9/L absolute lymphocyte count (ALC); Medium - Any measurable lymph node with the LD ≥5 cm but \<10 cm OR ≥25x10\^9/L ALC; High - Any measurable lymph node with the LD ≥10 cm or the presence of both ≥25x10\^9/L ALC and any measurable lymph node with the LD ≥5 cm but \<10 cm. Percentages have been rounded off to the nearest decimal point.
VEN + G: Reduction in Mandatory Hospitalizations During Venetoclax Ramp-up	Cycle 1 Days 22-28 up to Cycle 2 Days 1-7 (1 cycle=28 days)	Reduction in mandatory hospitalizations during venetoclax ramp-up in the VEN + G arm participants was defined as the actual number of protocol-mandated hospitalizations for TLS monitoring during venetoclax ramp-up period after 3 doses of obinutuzumab compared to the number of protocol-mandated hospitalizations for TLS monitoring during venetoclax ramp-up expected at baseline. Ramp-up period for venetoclax was defined as period from Cycle 1, Days 22-28, and Cycle 2, Day 1-Day 7 where the 20 mg and 50 mg daily doses of venetoclax, were administered for participants at TLS-high risk requiring mandated hospitalizations (the hospitalizations at 100, 200 and 400 was only needed if the participant had a TLS event at one of the lower doses). Total number of hospitalizations in high-risk TLS participants at baseline (expected to be N=2 hospitalization) was compared with the number of protocol mandated hospitalizations during the first 2 doses of the ramp-up.
Event-free Survival (EFS)	Up to approximately 74 months	EFS was defined as the time between the date of randomization and the date of PD/relapse, death, or the start of a new anti-leukemic therapy. PD was defined as any one of the following: appearance of any new lesion such as enlarged lymph nodes (≥ 1.5 cm); increase by ≥ 50% in greatest diameter of any previous site (≥ 1.5 cm); increase in the spleen/liver size by ≥ 50% or de novo appearance of splenomegaly/hepatomegaly; increase in blood lymphocytes by 50% or more with at least 5x10\^9/L B lymphocytes; transformation to a more aggressive histology; occurrence of cytopenia; posttreatment: progression of any cytopenia, documented by a decrease of Hb ≥ 2 g/dL or 10 g/dL, or by a decrease of platelet counts ≥ 50%/100x10\^9/L, which occurs at least 3 months after treatment.
Overall Survival (OS)	Up to approximately 74 months	OS was defined as the time between the date of randomization and the date of death due to any cause.
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)	From Day 1 until 28 days after the last dose of study drug, or until initiation of another anti-cancer therapy (up to 74 months)	An AE was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE was any AE that meets any of the following criteria: is fatal; is life-threatening; requires or prolongs inpatient hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to study drug; is a significant medical event in the investigator's judgment.
Number of Participants With Premature Withdrawals Due to AEs	From Day 1 until 28 days after the last dose of study drug, or until initiation of another anti-cancer therapy (up to 74 months)	An AE was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE was any AE that meets any of the following criteria: is fatal; is life-threatening; requires or prolongs inpatient hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to study drug; is a significant medical event in the investigator's judgment.

Trial Locations

Locations (40)

Medical Center of Aurora; 🇺🇸 Aurora, Colorado, United States

American Oncology Partners of Maryland, PA; 🇺🇸 Bethesda, Maryland, United States

University of Tennessee Medical Center;Office of Clinical Trials; 🇺🇸 Knoxville, Tennessee, United States

Oncology & Hematology Associates of Southwest Virginia, Inc._Goldschmidt; 🇺🇸 Roanoke, Virginia, United States

Canberra Hospital; 🇦🇺 Canberra, Australian Capital Territory, Australia

Liverpool Hospital; 🇦🇺 Liverpool, New South Wales, Australia

Port Macquarie - Mid North Coast Cancer Institute; 🇦🇺 Port Macquarie, New South Wales, Australia

Royal North Shore Hospital; 🇦🇺 St Leonards, New South Wales, Australia

Monash Health;Haematology Research; 🇦🇺 Clayton, Victoria, Australia

Peter MacCallum Cancer Centre;Clinical Haematology; 🇦🇺 Melbourne, Victoria, Australia

Northern Hospital;Oncology and/or Hematology; 🇦🇺 Melbourne, Victoria, Australia

Hopital Haut Leveque Chu de Bordeaux; 🇫🇷 Pessac, Aquitaine, France

Centre Hospitalier Régional Universitaire de Tours - Hôpital Bretonneau;Hématologie et Thérapie Cellulaire; 🇫🇷 Tours, Indre-et-Loire, France

Centre Hospitalier de Pérpignan;hématologie; 🇫🇷 Perpignan, Languedoc-Roussillon, France

Hopital Claude Huriez - CHU de Lille;service maladies appareil digestif; 🇫🇷 Lille, Nord, France

Centre Hospitalier intercommunal de Toulon La Seyne sur Mer; 🇫🇷 Toulon, Provence-Alpes-Côte-d'Azur, France

centre hospitalier lyon sud;Service Hématologie; 🇫🇷 Pierre-Bénite, Rhône, France

HENRI MONDOR HOSPITAL;Centre d'investigation clinique; 🇫🇷 Créteil, Val-de-Marne, France

Centre Hospitalier Universitaire de Caen Normandie; 🇫🇷 Caen, France

Centre Hospitalier Universitaire de Poitiers; 🇫🇷 Poitiers, France

Centre Hospitalier Universitaire de Reims - Hôpital Robert Debré;Hématologie Clinique; 🇫🇷 Reims, France

Azienda Ospedaliero Universitaria;Ematologia; 🇮🇹 Modena, Emilia-Romagna, Italy

Policlinico Umberto I; 🇮🇹 Roma, Lazio, Italy

Fondazione Policlinico Universitario Agostino Gemelli; 🇮🇹 Roma, Lazio, Italy

Ospedale San Martino;U.O. Clinica Ematologica; 🇮🇹 Genova, Liguria, Italy

Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico;U.O.C Ematologia; 🇮🇹 Milano, Lombardia, Italy

ASST Grande Ospedale Metropolitano Niguarda;Ematologia; 🇮🇹 Milan, Lombardia, Italy

Azienda Ospedaliero Universitaria Maggiore della Carità;SCDU Ematologia; 🇮🇹 Novara, Piemonte, Italy

Instituto Tumori Giovanni Paolo II;ONCOLOGIA MEDICA; 🇮🇹 Bari, Puglia, Italy

Ospedale Vito Fazzi;U.O. Ematologia IV Piano Polo Oncologico; 🇮🇹 Lecce, Puglia, Italy

AO Santa Maria della Misericordia; 🇮🇹 Perugia, Umbria, Italy

Hospital Germans Trias i Pujol; 🇪🇸 Badalona, Barcelona, Spain

COMPLEJO HOSPITALARIO DE NAVARRA;Servicio de Hematología; 🇪🇸 Pamplona, Navarra, Spain

Hospital Universitari Vall d'Hebron;Hematology; 🇪🇸 Barcelona, Spain

Hospital Universitario La Paz;Hematología; 🇪🇸 Madrid, Spain

Hospital General Universitario Morales Meseguer;Hematologia y Oncologia médica; 🇪🇸 Murcia, Spain

Hospital Universitario Virgen del Rocío;Unidad Onco-Hematología Pediátrica; 🇪🇸 Sevilla, Spain

Royal Hobart Hospital; 🇦🇺 Hobart, Tasmania, Australia

Clinique Victor Hugo- CCS du Mans; 🇫🇷 Le Mans, France

Hospital Universitario de Toledo; 🇪🇸 Toledo, Spain